Therapeutic Efficacy of TBC3711 in Pulmonary Hypertension
Author Information
Author(s): Kosanovic Djuro, Kojonazarov Baktybek, Luitel Himal, Dahal Bhola K, Sydykov Akylbek, Cornitescu Teodora, Janssen Wiebke, Brandes Ralf P, Davie Neil, Ghofrani Hossein A, Weissmann Norbert, Grimminger Friedrich, Seeger Werner, Schermuly Ralph T
Primary Institution: University of Giessen Lung Center, Giessen, Germany
Hypothesis
This study aims to investigate the therapeutic efficacy of the selective endothelin-A receptor antagonist TBC3711 in monocrotaline-induced pulmonary hypertension in rats.
Conclusion
The selective endothelin-A receptor antagonist TBC3711 demonstrates therapeutic benefit in rats with established pulmonary hypertension.
Supporting Evidence
- TBC3711 significantly reduced right ventricular systolic pressure compared to placebo.
- TBC3711 improved cardiac output in treated rats.
- TBC3711 reduced pulmonary vascular remodelling as shown by decreased medial wall thickness.
Takeaway
Researchers tested a new medicine called TBC3711 on sick rats to see if it could help their hearts and lungs work better, and it did!
Methodology
Male Sprague-Dawley rats were injected with monocrotaline and treated with TBC3711 or placebo, followed by various hemodynamic and histologic assessments.
Limitations
The study was conducted in rats, and some human disease characteristics may not be fully represented.
Participant Demographics
Adult male Sprague-Dawley rats, weighing 300-350 g.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website